Table 3

Glycemic, hypertension and lipid outcomes and management

Baseline
12 months prior to LC
During
12 months during LC
Post
12 months after LC
p Value over time
Mean (SD) Median Mean (SD) Median Mean (SD) Median
Glycemic outcomes and management, patients with A1c ≥7.3%(QIIP: N=153; control: N=157)
A1c value, %QIIP8.5 (1.25)8.18.1 (1.32)7.88.2 (1.62)7.90.10
Control8.5 (1.22)8.08.4 (1.51)8.08.4 (1.58)8.1
% % % p Value*
A1c at CPG target (≤7.0%)QIIPNo patients at target22.226.10.75
Control15.316.6
Prescribed an OHAQIIP84.388.290.20.99
Control82.887.987.3
Prescribed insulinQIIP28.839.247.10.24
Control35.042.749.7
Hypertension outcomes and management, all patients(QIIP: N=406; control: N=403)
N Mean (SD) N Mean (SD) N Mean (SD) p Value over time
Systolic BP value, mm HgQIIP344129.8 (16.24)394131.0 (17.17)400130.7 (16.56) 0.72
Control354132.0 (17.50)387130.7 (17.88)399131.7 (16.27)
Diastolic BP value, mm HgQIIP34474.0 (9.49)39473.6 (9.82)40073.0 (9.36) 0.92
Control35474.9 (10.81)38773.5 (10.73)39973.7 (10.50)
N % N % N % p Value over time
BP at CPG target (≤130/80)QIIP34453.839452.340052.80.50
Control35448.038750.939946.6
Prescribed an AHTNQIIP40679.140687.040689.20.22
Control40379.440384.940386.3
Lipid outcomes and management, all patients(QIIP: N=406; control: N=403)
N Mean (SD) N Mean (SD) N Mean (SD) p Value over time
LDL cholesterol value, mmol/LQIIP2842.2 (0.80)3692.1 (0.80)3852.0 (0.74)0.32
Control2732.4 (0.82)3532.3 (0.86)3822.2 (0.79)
N % N % N % p Value over time
LDL cholesterol at CPG target (≤2.0)QIIP28443.036952.638559.20.03
Control27334.835340.538244.5
% % % p Value over time
Prescribed a statinQIIP67.078.684.20.97
Control59.172.574.2